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An intact complement system is crucial for limiting
West Nile virus (WNV) dissemination. Herein, we
define how complement directly restricts flavivirus
infection in an antibody-independent fashion.
Mannose-binding lectin (MBL) recognized N-linked
glycans on the structural proteins of WNV and
Dengue virus (DENV), resulting in neutralization
through a C3- and C4-dependent mechanism that
utilized both the canonical and bypass lectin activa-
tion pathways. ForWNV, neutralization occurredwith
virus produced in insect cells, whereas for DENV,
neutralization of insect and mammalian cell-derived
virus was observed. Mechanism of action studies
suggested that the MBL-dependent neutralization
occurred, in part, by blocking viral fusion. Experi-
ments in mice showed an MBL-dependent acceler-
ated intravascular clearance of DENV or a WNV
mutant with two N-linked glycans on its E protein,
but not with wild-type WNV. Our studies show that
MBL recognizes terminal mannose-containing car-
bohydrates on flaviviruses, resulting in neutralization
and efficient clearance in vivo.
INTRODUCTION
The complement system is a primary innate defense against
invading pathogens. Several of its component proteins preferen-
tially recognize nonself structures on microbial surfaces and
initiate a cascade that leads to inflammation, opsonization,
and/or lysis of microorganisms (Jack et al., 2001). Three activa-
tion pathways are initiated by distinct recognition molecules and
converge in a common lytic pathway. The classical pathway is
activated by C1q binding to antigen-antibody complexes. The186 Cell Host & Microbe 8, 186–195, August 19, 2010 ª2010 Elsevielectin pathway is initiated by mannose-binding lectin (MBL) or
ficolin, both of which recognize sugar moieties on microbial
surfaces. Both the classical and lectin pathways activate C4
and C2, resulting in generation of the C4bC2a convertase that
cleaves C3 to C3b. In the alternative pathway, C3 spontaneously
turns over and can bind to pathogens. It then engages factor B,
which is cleaved by the serine protease factor D to generate an
alternative pathway C3 convertase (C3bBb). The binding of C3b
to C4b2a and C3bBb convertases converts them to C5 conver-
tases. These enzymes cleave C5 and promote assembly of
C5b-9membrane attack complex (MAC), which lyses pathogens
or infected cells. Complement has a protective role against many
viral infections (Avirutnan et al., 2008), and can reduce infectivity
by (1) inhibiting attachment to entry receptors and (2) promoting
adherence to and ingestion by phagocytes, and (3) through
mechanisms that require C5 and do or do not result in virolysis
(Friedman et al., 2000).
MBL is a C-type multivalent lectin that is synthesized predom-
inantly in the liver and circulates in blood. In humans, a single
MBL protein is expressed, whereas mice have two proteins,
MBL-A and MBL-C, encoded by the genes MBL1 and MBL2,
respectively. Mouse and human MBL bind specific carbohy-
drates on the surface of pathogens and necrotic or apoptotic
cells (Ip et al., 2009). MBL binds to repeating arrays of mannan,
N-acetylglucosamine, lipoteichoic acid, phospholipids, and
nucleic acids (Takahashi et al., 2006). MBL has a relatively low
affinity for monosaccharide and other carbohydrate ligands,
requiring multivalent lectin domain interactions for recognition,
specificity, and efficient complement activation (Jack et al.,
2001). MBL binding activates C4 and C2 through its associated
proteases, MBL-associated serine proteases (MASPs). At least
three MASP proteins have been identified (MASP-1, -2, -3),
with MASP-2 having a dominant role in cleaving C4 and C2
(Takahashi et al., 2007). Studies using MBL A/ 3 MBL-C/
mice have established roles for MBL in limiting Staphylococcus
aureus (Shi et al., 2004) and herpes simplex virus (Gadjeva
et al., 2004) infections. In humans, polymorphisms in the MBL
gene are well characterized, and individuals with variant allelesr Inc.
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MBL Neutralization of Flaviviruseshave decreased serum levels (Tsutsumi et al., 2005). Low serum
MBL concentrations are associated with an increased risk of
disseminated disease with Neisseria meningitides (Bathum
et al., 2006) and have been suggested to increase susceptibility
to HIV (Tan et al., 2009), hepatitis B (Chong et al., 2005), and
herpes simplex virus (Seppanen et al., 2009) infections.
Flaviviruses are enveloped, positive-polarity RNA viruses that
cause significant human disease globally and include West Nile
(WNV), Dengue (DENV), yellow fever, and tick-borne encephalitis
(TBEV) viruses. Many flaviviruses are arthropod transmitted and
infect humans or other vertebrate animals through insect
vectors. The mature flavivirus is an 50 nm icosahedral particle,
composed of a nucleocapsid surrounded by a lipid bilayer that is
coated with envelope (E) and membrane (M) proteins. The flavi-
virus E protein contains a variable number (0, 1, or 2) of N-linked
glycans that are believed to contribute to viral attachment and
cell tropism. Most WNV strains have only one glycosylation site
at E-154 in domain I, whereas virtually all DENV isolates have
a second N-linked glycan at position E-67 in domain II. Differ-
ences in N-linked glycosylation of E result in differential binding
to the viral attachment receptors DC-SIGN and DC-SIGN-R
(Davis et al., 2006a, 2006b; Tassaneetrithep et al., 2003). Corre-
lations between the number and location of N-linked glycosyla-
tion sites on E and the neuroinvasiveness of WNV also have
been reported (Beasley et al., 2005). The precursor form of the
M protein (prM) of DENV and WNV has one additional N-linked
glycan, although its exact location is variable among flavivirus
family members.
In mice, an intact complement system is crucial for limiting
WNV dissemination. Mice deficient in the central component
C3 uniformly succumb to WNV infection (Mehlhop et al.,
2005), and mice lacking C4, factor B, or C1q show greater
susceptibility to WNV infection (Mehlhop and Diamond, 2006).
A preliminary study demonstrated that naive mouse serum
could neutralize WNV in vitro in the absence of immune anti-
body (Mehlhop et al., 2005). We speculated that this effect
might be mediated by complement deposition onto the virion,
thereby preventing infection of host cells. Herein, we defined
the mechanism by which naive serum and complement directly
inhibit flavivirus infection. MBL recognizes terminal mannose
containing carbohydrate ligands on the surface of flaviviruses,
resulting in virus neutralization and more efficient clearance
in vivo.
RESULTS
Serum MBL Binds to WNV and Neutralizes Infection
Given that complement has direct opsonic function against
bacteria, fungi, and some viruses, we evaluated whether it could
directly recognize WNV and neutralize infection. We initially
focused on the activity of the complement recognition protein
MBL because the structural proteins prM and E display N-linked
glycans and contain terminal mannose sugars after replication
in mosquitoes (Hsieh and Robbins, 1984). To test for binding of
MBL to WNV, we utilized a capture ELISA in which infectious
virions were bound to wells of a microtiter plate with an anti-
WNV mAb. Immobilized insect cell-derived WNV was incubated
with serum from naive wild-type C57BL/6 mice, followed by
detection with an antibody against MBL-C, the major MBLCell Hosubtype in mouse serum. Notably, mouse MBL-C bound effi-
ciently to WNV, and as expected, binding was Ca2+ dependent
and inhibited by soluble mannan (Figure 1A). The specificity of
the interaction was confirmed by an absence of signal when
serum from wild-type mice was heat inactivated or when serum
from MBL-A/ 3 MBL-C/ mice was used (Figure 1B).
We next assessed whether MBL binding would inhibit WNV
infectivity.WNV infection of BHK21 cells was tested in amodified
plaque reduction assay after preincubating virus in solution with
naive serum from wild-type orMBL-A/3MBL-C/mice. We
observed a reduction in viral infectivity whenWNV samples were
pretreated with wild-type serum at concentrations of greater
than 1% (Figure 1C). This activity was abolished after heat inac-
tivation, confirming that a labile complement component was
responsible (data not shown). Infectivity was not reduced after
pretreatment of WNV with serum from MBL-A/ 3 MBL-C/
mice, indicating that neutralization was MBL dependent
(Figure 1C). Indeed, reconstitution of serum from MBL-A/ 3
MBL-C/ mice with recombinant mouse MBL-C neutralized
WNV to a similar degree as serum from wild-type mice
(Figure 1D). As serum from C57BL/6 mice contains 30 mg/ml
MBL-C (Liu et al., 2001), the addition of 3 mg/ml of recombinant
MBL-C to diluted sera from MBL-A/ 3 MBL-C/ mice is
comparable with the concentration in wild-type serum. Serum
from RAG1/ mice, which lack B and T cells, also reduced
WNV infectivity, confirming that neutralization did not require
antibody (Figures 1C and 1E).
MBL-Dependent Neutralization of WNV Requires
Complement Activation
Although our experiments implicated a role for MBL in serum-
dependent neutralization of WNV, it remained unclear whether
this required activation of downstream complement compo-
nents. To evaluate this, we pretreated WNV with naive sera
from several mouse strains deficient in different complement
components. The neutralizing effect of serum on WNV was
dependent on MBL and MASP-2 yet independent of C1q or C5
(Figure 1E). A lack of requirement of C5 indicates that serum-
dependent neutralization does not occur by the MAC and viroly-
sis, and is consistent with in vivo studies showing no change in
WNV infection in C5/ mice (Mehlhop et al., 2009a). Notably,
an absence of both C3 and C4 (C3/3 C4/ DKO) abrogated
the inhibitory effect of serum. This suggests that MBL binding
alone does not restrict WNV infection, but rather, complement
activation was necessary. Consistent with this, C3 deposition
on virions was detected in the presence of wild-type serum,
but not with serum from MBL-A/ 3 MBL-C/, MASP-2/,
or C3/ mice (Figure 1G). Because an absence of C4 only
partially inhibited MBL-induced neutralization (Figure 1E),
complement activation must occur through both the canonical
lectin (C4-dependent) and the C2 bypass (C4-independent)
pathways (Selander et al., 2006). Analogously, because a defi-
ciency of C3 only partially inhibitedMBL-triggered neutralization,
deposition of C2 and C4may be sufficient for viral neutralization,
without the absolute requirement of downstream C3 activation
and deposition (Figure 1H). The induction of both MBL-initiated
pathways likely explains the partial inhibitory phenotypes of
either C3/ or C4/ serum, yet absence of neutralization by
C3/ 3 C4/ DKO serum.st & Microbe 8, 186–195, August 19, 2010 ª2010 Elsevier Inc. 187
Figure 1. MBL Binds to WNV Virions and
Neutralizes Infection in a MASP-2- and C3-
Dependent Pathway
(A and B) WNV virions were captured using
an anti-WNV E protein-specific mAb and incu-
bated with naive serum from wild-type (WT)
(A and B) or MBL-A/ 3 MBL-C/ mice (MBL-
A/C KO) (B). MBL-C binding toWNV was detected
with an anti-MBL-C mAb. MBL-C binding was
inhibited by the presence of 10 mM EDTA,
100 mg/ml mannan, or heat inactivation (WT HI
serum). The data are representative of two to
three independent experiments performed in
duplicate.
(C) WNV was preincubated with naive serum from
wild-type, MBL-A/ 3 MBL-C/, or RAG1/
mice. Virus was added to BHK21 cells and the
infectivity determined 3 days later by plaque
assay. The data are representative of two inde-
pendent experiments performed in duplicate.
(D) The addition of recombinant MBL-C to serum
from MBL-A/ 3 MBL-C/ mice restores
neutralization of WNV. The data are representative
of three independent experiments performed in
duplicate.
(E) Neutralization of WNV in the presence of 10%
(v/v) complement-deficient serum. Data are pre-
sented as percent neutralization (% reduction of
plaque numbers over wild-type heat-inactivated
serum) by a given complement-deficient or anti-
body-deficient (RAG1/) serum. Data are pooled
from up to 15 independent experiments, and
asterisks indicate values that are statistically
different (p < 0.05) than that of wild-type C57BL/
6 serum.
(F) MBL-dependent neutralization does not promote virolysis. WNV was treated with media, detergent (NP-40, positive control), or serum from wild-type
(untreated or heat-inactivated) or MBL-A/ 3 MBL-C/ mice. RNase A was added, after which viral RNA was harvested and subjected to RT-PCR. The
data are the average of four independent experiments, and the dashed line indicates the limit of detection of the assay.
(G) C3 deposition on insect cell-derived WNV was measured in a capture ELISA using an anti-mouse C3 detection antibody and serum from various deficient
mouse strains. One representative experiment of three is shown.
(H) Scheme of the lectin pathway of complement activation. MBL binding induces activation of C3 either via C4 and C2, or through a C2 bypass pathway.
(I) Mouse dendritic cells were infected with WNV that was pretreated without serum, or with serum (untreated or heat inactivated) from wild-type orMBL-A/3
MBL-C/mice. One day later, virus was harvested from supernatants and titrated by plaque assay. The data are an average of three independent experiments
performed in triplicate, and asterisks indicate values that are statistically different (p < 0.04). Error bars represent standard deviation (B, D–G, and I) or standard
error of the mean (A and C).
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and Cell Lines
The experiments establishing MBL-dependent neutralization of
WNV were performed with a transformed BHK21 fibroblast cell
line. To confirm that this observation was not cell type restricted,
studies were repeated in mouse bone marrow-derived dendritic
cells. Mouse serum efficiently inhibited WNV infection in
dendritic cells in anMBL-dependent manner (Figure 1I). A similar
MBL-dependent neutralization of WNV was observed with
BHK21-DC-SIGN-R or Raji-DC-SIGN-R cells (see Figure S1A,
available online, and data not shown); these cells transgenically
express a lectin attachment receptor that binds N-linked glycans
on the structural proteins of WNV and facilitates infection (Davis
et al., 2006b). Finally, the addition of serum containing MBL also
reduced antibody-dependent enhancement of WNV infection
with a mAb (E34, IgG1) that lacks the ability to efficiently bind
C1q (Figure S1B).188 Cell Host & Microbe 8, 186–195, August 19, 2010 ª2010 ElsevieMBL Binds to Terminal Mannose N-Linked Glycans
on WNV
To define the recognition determinant, we examined the state of
the N-linked glycans on WNV derived from mosquito and
mammalian cells. Previous experiments with different flavivi-
ruses produced in insect cells have shown that although TBEV
and some DENV serotypes contained endoglycosidase H
(Endo H)-sensitive high-mannose N-linked oligosaccharide
side chains, Murray Valley encephalitis virus and other DENV
serotypes displayed Endo H-resistant pauci-mannose-contain-
ing N-linked glycans (Hacker et al., 2009; Winkler et al., 1987);
pauci-mannose N-linked glycans are present in invertebrate
cells as a result of processing of the high-mannose (Man9-
GlcNAc2) side chains to shorter variants (e.g., Man4GlcNAc2)
(Schachter, 2009). DENV produced in mammalian cells has
N-linked glycans that are a mixture of high-mannose and
complex glycans (Hacker et al., 2009). In our case, C6/36 Aedesr Inc.
Figure 2. MBL Binds Strongly to and Neutralizes Insect Cell-Derived
but Not Mammalian Cell-Derived WNV
(A) Western blot of E protein fromWNV virions produced in (left) insect (C6/36)
or (right) mammalian (BHK21) cells. To assess the type of N-linked glycan on
WNV E proteins, samples were treated with Endo H (H) or PNGase F (F).
(B) MBL-C binding was assayed after WNV generated from insect or mamma-
lian cells was incubated with serum from wild-type orMBL-A/ 3MBL-C/
mice as described in Figure 1. Equal virus loading of microtiter wells was
confirmed by detection with an anti-WNV E protein mAb performed in parallel
(data not shown). The data are an average of two independent experiments
performed in duplicate.
(C) Insect or mammalian cell-derived WNV was incubated with untreated or
heat-inactivated naive serum from wild-type or MBL-A/ 3 MBL-C/
mice, and C3 deposition was measured by ELISA as described in Figure 1.
The data are an average of three independent experiments performed in dupli-
cate, and asterisks indicate values that are statistically different (p < 0.05) than
those observed in the absence of virus.
(D) Serum neutralization ofWNV derived fromC6/36 or Vero cells. Experiments
were performed as in Figure 1, with a final concentration of 10% of the indi-
cated serum. The data are representative of two independent experiments
performed in duplicate. Error bars represent standard deviation (B and C) or
standard error of the mean (D).
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partially Endo H-sensitive high-mannose form, whereas BHK21
mammalian cell-derived WNV contained exclusively Endo
H-resistant carbohydrates (Figure 2A).
MBL readily bound to WNV generated in C6/36 insect cells,
but not monkey Vero cells or hamster BHK21 cells (Figure 2B
and data not shown). Moreover, C3 deposition was detected
only on virus derived from insect cells (Figure 2C). Consistent
with this, preincubation of Vero or BHK21 cell-derived WNV
with wild-type naive serum did not reduce infectivity (Fig-
ure 2D and data not shown). These results suggest that efficient
MBL binding, complement activation, and neutralization occur
preferentially with insect and not mammalian cell-derived
WNV. The interaction of MBL with insect cell-derived virus is
likely a result of binding to high and pauci-mannose N-linked
glycans.
To confirm these observations, we passaged WNV in BHK21
cells in the presence of deoxymannojirimycin (DMJ), an inhibitor
of the endoplasmic reticulum a-(1,2) mannosidase I. Treatment
with DMJ prevents the addition of complex sugar groups to
N-linked glycans, resulting in glycoproteins that display high-
mannose (Man9GlcNAc2) sugars. If MBL recognized terminal
mannose moieties on the structural glycoproteins of insect-cell
derived WNV, then virus generated in BHK21 cells in the pres-
ence of DMJ should become sensitive to MBL neutralization.
Indeed, WNV from DMJ-treated BHK21 cells displayed Endo-
H-sensitive N-linked glycans, efficiently bound MBL, and was
neutralized by serum from wild-type but not MBL-A/ 3
MBL-C/ mice (Figures 3A–3C).
MBL Binds to DENV and Neutralizes Infection
The four DENV serotypes are mosquito-transmitted flaviviruses
that cause a febrile illness in humans that can progress to hemor-
rhagic fever and shock syndrome. Unlike WNV, most DENV
strains contain E proteins with N-linked glycosylation sites
in both domains I (N153) and II (N67); the N-linked glycan in
domain II can be displayed in the high-mannose form even in
mammalian cells (Hacker et al., 2009) and allows recognition of
DC-SIGN (Davis et al., 2006a; Lozach et al., 2005), which
requires high-mannose carbohydrates as ligands. Aswe hypoth-
esized that two N-linked glycans on DENV E protein would facil-
itate enhanced MBL binding and neutralization, we performed
studies with DENV serotype 2 (DENV-2). Insect cell-derived
DENV-2 was recognized and neutralized by serum in an MBL-
dependent manner (Figures 4A and 4B). In contrast to WNV,
mammalian cell-derived DENV-2 infectivity was also inhibited
by naive wild-type serum (Figure 4C). To determine whether
a second N-linked glycan at E-67 could facilitate MBL recogni-
tion and neutralization of mammalian cell-derived WNV, we
engineered a mutant WNV with the corresponding amino acid
change (D67N) (Figure 4D). However, when virus was propa-
gated inmammalian cells, only modest increases inMBL binding
and serum inhibition (36% versus 3% neutralization with wild-
type virus, p = 0.0004) of the D67N mutant were observed
compared to the parent WNV (Figures 4E and 4F); this may
have been due to incomplete addition or inefficient processing
of N-linked glycans at the E-67 site (Figure 4D). In comparison,
insect cell-derived parent and D67N WNV were bound and
neutralized by MBL efficiently (Figures 4E and 4G).Cell Host & Microbe 8, 186–195, August 19, 2010 ª2010 Elsevier Inc. 189
Figure 3. MBL Binds and Neutralizes
Mammalian Cell-Derived WNV Generated
in the Presence of the a-(1,2) Mannosidase
I Inhibitor DMJ
WNV was generated in BHK21 cells in the pres-
ence or absence of DMJ.
(A) Western blot showing differences in E protein
migration after treatment with (H) Endo H or (F)
PNGase F of virus generated in BHK21 cells in
the absence or presence of DMJ. The panel shows
one of two experiments with identical results.
(B and C) MBL binding (B) and serum neutralization (C) of WNV from BHK21 cells that were untreated or treated with DMJ were tested as described in Figure 1.
The data are representative of two independent experiments performed in duplicate. Error bars in this figure represent standard deviations.
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MBL Neutralization of FlavivirusesTo determine whether MBL recognition and neutralization
can be generalized to other arthropod-transmitted RNA viruses,
we assessed serum inhibition of Chikungunya virus (CHIKV), an
arthritogenic alphavirus with potential for explosive urban
epidemics. The structural glycoproteins of insect cell-derived
CHIKV, E1 and E2, each contain two N-linked glycans (Simizu
et al., 1984) in the high-mannose form (Figure 5A), which could
represent binding sites for MBL. In contrast to WNV and
DENV, insect cell-derived CHIKV virus was not neutralized by
naive wild-type mouse serum (Figure 5B). Similarly, insect cell-
passaged Sindbis virus (SINV), a second arthritogenic alphavirus
that has two N-linked glycans on each of its structural proteins
(Burke and Keegstra, 1979), also was not neutralized by serum
(Figure 5C). Consistent with this, little direct binding of MBL to
CHIKV was demonstrated in a virus capture ELISA (Figure 5D).
Hence, MBL-mediated neutralization is effective against some,
but not all, mosquito-derived viruses that display multiple
N-linked glycans on their envelope proteins.
MBL Opsonization Partially Blocks Viral Fusion
Our experiments established that MBL neutralizes flavivirus
infection after binding and complement deposition, yet they
did not identify a mechanism of inhibition. Although complement
can inhibit HIV directly by virolysis (Spear et al., 1991), C5 was
not required for WNV neutralization (Figure 1E). MBL opsoniza-gated inmammalian or insect cells and assessed for (E)MBLbinding and (F) and (G
experiments, respectively, performed in duplicate. Error bars represent standard
190 Cell Host & Microbe 8, 186–195, August 19, 2010 ª2010 Elsevietion also did not promote virolysis through a C5-independent
mechanism. Neutralization by MBL in solution did not render
encapsidated viral RNA sensitive to degradation by RNase A.
The levels of WNV RNA in solution were unchanged between
viral samples treated with serum from wild-type or MBL-A/ 3
MBL-C/ mice (Figure 1F). Thus, we speculated that MBL
binding and complement deposition on WNV might interfere
with attachment to entry receptors or viral fusion with host
membranes. To test the former hypothesis, WNV was mixed
with serum from wild-type or MBL-A/ 3 MBL-C/ mice to
allow complement deposition on the virion. After cooling, virions
were allowed to attach to BHK21 cells on ice. After removal of
unbound virus, cells were lysed, and viral RNA was measured.
We observed no appreciable difference in levels of bound viral
RNA after incubation with serum from wild-type or MBL-A/ 3
MBL-C/ mice at either 4C or 37C (Figure 6A and data not
shown).
To test whether MBL binding and complement deposition
neutralized infection by inhibiting viral fusion, we adapted
a plasma membrane fusion assay (Vashishtha et al., 1998).
WNV was pretreated with serum from wild-type or MBL-A/ 3
MBL-C/mice, and, after cooling, adsorbed to BHK21 cells on
ice. After several washes to remove unbound virus, fusion at
the plasma membrane was triggered, albeit inefficiently, after
a brief exposure to low pH (5.5) containing media at 37C. CellsFigure 4. MBL-Dependent Neutralization
of DENV
(A) MBL binding and serum neutralization of
DENV-2 were assessed using a virus capture
ELISA (A) and plaque assay (B and C), respec-
tively. DENV-2 was generated in insect cells for
(A) MBL ELISA and (B) serum neutralization or in
BHK21 mammalian cells (C) for neutralization.
The data are an average of two to four indepen-
dent experiments performed in duplicate. (D)
A mutant WNV was engineered with a ‘‘Dengue-
like’’ glycosylation pattern in E (two N-linked
glycan sites, D67N and N154) and was propa-
gated in the presence or absence of DMJ in
BHK21 cells. A western blot with anti-E MAbs of
virions after treatment with Endo H (H) or PNGase
F (F) treatment is shown. Note, the D67N showed
incomplete addition of N-linked glycans to the
WNV E protein. As a control, D67N viral isolates
were sequenced and showed complete preserva-
tion of the mutation. (E–G) D67N WNV was propa-
) serumneutralization. The data are representative of two and four independent
deviation (A and E–G) or standard error of the mean (B and C).
r Inc.
Figure 5. MBL Does Not Neutralize Alphavi-
rus Infection
(A) Western blot of CHIKV E1 and E2 proteins from
insect cell passaged virus with and without treat-
ment of (H) Endo H or (F) PNGase F.
(B and C) Neutralization of (B) CHIKV and (C) SINV
was assessed in the presence or absence of wild-
type serum as described in Figure 1.
(D) MBL binding to CHIKV was evaluated using
a modified virus capture ELISA as described in
Figure 1. As a positive control, MBL-C in wild-
type serum bound to mannan (left column).
However, MBL-C binding was not detected to
either CHIK Fab fragments alone or with CHIKV
(middle and right columns). Detection with mAb
E11 (anti-E2) antibody (right panel) demonstrates
the level of virus addition in microtiter wells. The
data are representative of two to three indepen-
dent experiments performed in duplicate. Error
bars in this figure represent standard deviations.
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MBL Neutralization of Flaviviruseswere incubated for 24 hr in the presence of 20 mM NH4Cl to
prevent virus entry via endosomal pathways. Measurement of
the percentage of WNV-antigen (E or NS1 proteins) positive cells
by flow cytometry monitored the efficiency of plasmamembrane
fusion. Notably, serum from wild-type mice strongly inhibited
plasma membrane fusion and infection (Figures 6B and 6C and
Figure S2); part of the infectivity was restored in serum from
MBL-A/ 3 MBL-C/ mice. Thus, MBL binding and comple-
ment deposition onWNV neutralizes infection, in part by prevent-
ing viral fusion with host cell membranes.
MBL Deposition Accelerates Viral Clearance In Vivo
Our in vitro experiments suggested that MBL and complement
activation neutralized WNV that displayed N-linked glycans
containing terminal mannose residues. In vivo, MBL-dependent
virus neutralization could occur on a cellular level by blocking
fusion or at a systemic level by removing virus from circulation.
Complement-opsonized virus may be sequestered by comple-
ment receptor expressing cells of the reticuloendothelial
system in the spleen, liver, and lung (Jahrling et al., 1983). To
evaluate the significance of MBL-dependent opsonization, we
analyzed its effect on clearance of WNV in vivo. Wild-type and
MBL-A/ 3 MBL-C/ mice were inoculated intravenously
(i.v.) with 53 104 PFU of WNV derived from insect cells, and viral
RNA in serum was analyzed over time. Clearance of wild-type
WNV from the circulation was rapid but was not appreciably
affected by an absence of MBL (Figure 7A). We also tested the
clearance of the WNV D67N mutant that contains a second
N-linked glycan on the E protein. The D67N virus was removed
from circulation in wild-type mice more rapidly than the parent
strain; however, this effect was lost in MBL-A/ 3 MBL-C/,
MASP-2/, and C3/ mice but not RAG1/ mice (Figures
7B and 7D); thus, the rapid clearance in blood of WNV D67N
required MBL binding and C3 activation but not antibody. As
a deficiency of MBL delayed the clearance of the D67N but not
wild-type WNV, we hypothesized that MBL might have a domi-
nant role in clearing from circulation flaviviruses with a second
N-linked glycan on the E protein. Accordingly, experimentsCell Howere repeated with the Western Pacific-74 strain of DENV
serotype 1 (DENV-1); this strain was selected because it is
pathogenic in some strains of mice (B. Shrestha and M.S.D.,
unpublished data) and displays Endo H-sensitive high-mannose
N-linked glycans on its E protein, even when produced in
mammalian cells (Hacker et al., 2009). Notably, Vero cell-derived
DENV-1 disappeared rapidly from the serum of wild-type
mice, whereas delayed clearance kinetics were observed in
MBL-A/3MBL-C/mice (Figure 7C). Thus, MBL-dependent
clearance appearsmore important for flaviviruses that display an
additional N-linked glycan at position E-67 on the E protein.
DISCUSSION
In this report, we demonstrate that MBL, a pathogen-recognition
molecule of the complement system, binds to flaviviruses and
activates complement, leading to inhibition of viral infectivity in
the absence of antibody. Neutralization is mediated through
the activation of MASP-2 and both the canonical lectin and C2
bypass pathways, which deposit complement on the virion
surface and, in part, prevent viral fusion with host membranes.
Our experiments show that MBL neutralization depends on the
type and extent of N-linked glycosylation on the structural
E protein, as differences were observed between mammalian
and insect cell-derived viruses. Finally, in vivo studies suggest
that MBL-dependent clearance from circulation occurs prefer-
entially with flaviviruses that display N-linked glycans on E at
position E-67. Given that wild-type WNV lacks an N-linked
glycan at E-67, complement-dependent intravascular clearance
is likely more physiologically relevant for DENV.
Although MBL binding and complement deposition have been
demonstrated for many microorganisms, the exact roles that
MBL plays in defense remain unknown. Our study identifies
a direct effect of MBL and complement in inhibiting flaviviruses
in the absence of natural or antiviral antibody. Neutralization
of WNV infectivity by MBL was completely dependent on
MASP-2 and partially dependent on fB, yet independent of
C1q and C5. An absence of C3 or C4 alone only partially reducedst & Microbe 8, 186–195, August 19, 2010 ª2010 Elsevier Inc. 191
Figure 6. MBL-Mediated Complement Activation Neutralizes WNV
Infectivity Likely by Blocking Viral Fusion
(A) MBL binding to WNV does not inhibit viral attachment to host cells. WNV
was preincubated with heat-inactivated (Wild-Type HI) or untreated (Wild-
Type) serum from C57BL6 mice, or with serum from MBL-A/ 3 MBL-C/
mice. Serum-opsonized virus was cooled and added to BHK21 cells on ice.
After extensive washing, attachment was assessed by qRT-PCR. The data
are representative of three independent experiments performed in triplicate.
No statistically significant difference was observed.
(B and C) WNV fusion at the plasma membrane is impaired following incuba-
tion with serum from wild-type but not MBL-A/ 3 MBL-C/ mice. Serum-
opsonized WNV was incubated with BHK21 cells to allow viral attachment.
Viral fusion at the plasma membrane was induced after a brief exposure to
a low pH (5.5) buffer. After pH neutralization, cells were cultured for 24 hr in
the presence of NH4Cl to inhibit viral infection through the endosomal
pathway. Cells were analyzed for the presence of intracellular virus by staining
with an anti-E protein mAb. Representative histograms are shown (C), and the
data were pooled from four experiments performed for statistical analysis (B).
Asterisks indicate values that are statistically different (p < 0.05). Note the effi-
ciency of low pH-triggered viral fusion at the plasma membrane is much lower
than that observed with endosomal fusion pathways. Error bars in this figure
represent standard deviations.
Figure 7. WNV D67N Mutant and DENV Are Cleared from the Circu-
lation of Mice with Faster Kinetics in an MBL-Dependent Manner
(A and B) Clearance of insect cell-derived WNV in mice. Wild-type or
MBL-A/ 3 MBL-C/ mice were inoculated with 5 3 104 PFU of (A) parent
wild-type or (B) D67N mutant WNV by an intravenous route. Blood was
collected at 0.5, 3, and 6 hr postinjection, and viral RNA in serum was
measured. The results are from eight to ten mice per group, and asterisks indi-
cate differences that are statistically significant (p < 0.05).
(C) Wild-type andMBL-A/3MBL-C/mice were infected i.v. with 106 PFU
of DENV-1. After harvesting blood at the indicated times, viral RNA in serum
wasmeasured. The results are from eight to ninemice per group, and asterisks
indicate differences that are statistically significant (p < 0.05).
(D) Clearance of insect cell-derived WNV D67N in mice requires C3 activation
but not antibody. Wild-type,MBL-A/3MBL-C/,MASP-2/, C3/, and
RAG1/mice were inoculated with 53 104 PFU of WNV D67N by an intrave-
nous route. Blood was collected at 0.5 hr postinjection, and viral RNA in serum
wasmeasured. The results are from seven to tenmice per group, and asterisks
indicate differences that are statistically significant (p < 0.05).
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inhibited serum neutralization. Thus, MBL opsonization is not
sufficient for neutralization, as C3 and/or C4 deposition is
required. The results are consistent with a model in which MBL
initiates C4-dependent/C3-independent inhibition by the canon-
ical lectin pathway and C4-independent/C3-dependent neutral-
ization by a C2 bypass pathway (Dumestre-Perard et al., 2008;
Selander et al., 2006) (see Figure 1H). Although in the canonical
lectin pathway C4 and C2 activation typically leads to C3 depo-
sition, C3was not absolutely required for reducing viral infectivity
in our experiments. Thus, the deposition of either C4 (canonical
lectin pathway) or C3 (C2 bypass pathway) onto virions appears
sufficient for neutralization.192 Cell Host & Microbe 8, 186–195, August 19, 2010 ª2010 ElsevieMBL binding to flaviviruses was modulated by the level and
processing of carbohydrates present on the N-linked glycans
of the E protein. Multivalent MBL recognizes arrays of terminal
D-mannose, L-fucose, and N-acetyl-D-glucosamine (GlcNAc),
which are commonly found on microorganisms (Ip et al., 2009).
MBL bound to WNV derived from insect cells, which produce
proteins with high and pauci-mannose carbohydrates. Mamma-
lian cell-derived WNV that displays trimmed, processed
complex, and hybrid N-linked glycans was poorly recognized
by MBL. Genetic engineering of a second E protein N-linked
glycosylation site at E-67 into WNV improved MBL binding and
complement-dependent neutralization, even when virus was
generated in mammalian cells. The second E protein N-linked
glycan at E-67 may enhance the avidity of MBL binding
by increasing the density of carbohydrates, or, alternatively,
carbohydrates at this site may not be fully processed (Davis
et al., 2006a; Hacker et al., 2009); indeed, because of this,
DENV is able to use DC-SIGN, a cell-surface lectin that recog-
nizes high-mannose-sugar groups, as an attachment receptor
(Lozach et al., 2005; Tassaneetrithep et al., 2003).
Complement can directly neutralize viral infectivity by different
mechanisms. Coating of virions with complement components
can inhibit sterically the interaction of viruses with host cellr Inc.
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(Jayasekera et al., 2007; Ji et al., 2005). However, WNV binding
to BHK21 cells was unaltered in the presence of wild-type
serum, excluding a role for complement in inhibiting attachment
on this cell type. Complement also can restrict viral infections in
a C5-dependent manner through the deposition of the MAC, or
through a mechanism that does not require virolysis (Friedman
et al., 2000). MBL-dependent neutralization of WNV, however,
was independent of C5 and did not induce virolysis. Our studies
suggest a mechanism in which MBL and complement neutralize
WNV, in part by inhibiting pH-dependent fusion with host
membranes. MBL binding and C3 or C4 deposition may interfere
with the structural rearrangements of the E protein during viral
fusion. This could occur in a manner analogous to crosslinking
of WNV E proteins by C1q and antibody, which decreased the
stoichiometric requirements for neutralization (Mehlhop et al.,
2009b).
Remarkably, insect cell-derived CHIKV or SINV, enveloped
alphaviruses with four N-linked glycans on their E1 and E2
proteins, were not neutralized by serum complement. Although
earlier studies with SINV suggested that complex-type N-linked
glycans can be generated on alphavirus structural proteins in
insect cells (Hsieh and Robbins, 1984), our biochemical studies
with CHIKV produced in insect cells confirmed that the N-linked
glycans on E1 and E2 were Endo H sensitive. Alphaviruses may
have evolved a specific immune evasion mechanism to avoid
recognition and neutralization by MBL, or, alternatively, not all
high-mannose sugar arrays are recognized equivalently byMBL.
Our in vivo experiments demonstrate that neutralization and
clearance from circulation are separable processes that are
both regulated by MBL. Whereas insect cell-derived wild-type
WNVwas neutralized by complement in cell culture experiments,
no difference in the rate of serum clearance was observed in
wild-type or MBL-A/ 3 MBL-C/ mice. Nonetheless, insect
cell-derived WNV, in the presence or absence of MBL, was
still rapidly cleared from circulation. This could be due to viral
sequestration and removal in different visceral organs (Jahrling
et al., 1983). Although wild-type WNV was cleared equivalently
from the serum of wild-type and MBL-A/ 3 MBL-C/ mice,
differences were observed with virus strains displaying two
N-linked glycans on the viral E protein. Both WNV D67N and
DENV-1 were removed from the circulation of wild-type mice
with accelerated kinetics compared to MBL-A/ 3 MBL-C/
mice. Thus, binding of MBL to flaviviruses that display E-67
N-linked glycans promotes viral clearance from circulation.
Finally, our experiments withMASP-2/ and C3/mice estab-
lish that removal from circulation requires MBL-triggered
complement activation.
A deficiency of MBL is common in humans due to gene poly-
morphisms, resulting in low expression or functionally impaired
MBL (Thiel et al., 2006). Most MBL-deficient individuals do not
show increased susceptibility to infections, although some
appear at higher risk of infection with Neisseria meningititis
and HIV. Our experiments suggest that a more detailed analysis
of MBL deficiency, and its effects on the severity of flavivirus
infection in humans may be warranted. MBL opsonization and
complement activation under certain circumstances could
have pathogenic consequences. C3 and C4 catabolism during
secondary DENV infection correlates with disease severityCell Ho(Bokisch et al., 1973; Nascimento et al., 2009). Moreover,
humans with wild-type MBL genotypes showed increased lectin
pathway activation that associated with an increased risk of
dengue hemorrhagic fever (Acioli-Santos et al., 2008; Nasci-
mento et al., 2009). Thus, MBL recognition of flaviviruses could
have different outcomes depending on the virus strain, the extent
and type of glycosylation on the structural proteins, and the
intrinsic pathogenesis sequence.
EXPERIMENTAL PROCEDURES
Mice, Cell Lines, and Reagents
C3/, C4/, C3/ 3 C4/, C1q/, and fB/ mice on a C57BL/6 back-
ground were obtained from colleagues (C. Gerard, M. Carroll, G. Stahl, M.
Botto, J. Atkinson, and H. Molina). MASP-2/ mice were generated at the
University of Leicester and backcrossed onto the C57BL/6 background for
nine generations. MBL-A/ 3 MBL-C/ mice on a C57BL/6 background
were purchased (Jackson Laboratories), as were wild-type and C5/
B10.D2 mice (Taconic). Animal studies were performed with approval of the
Washington University School of Medicine Animal Safety Committee.
Raji and BHK21 cells stably expressing the cell-surface lectin DC-SIGN-R
were cultured as described (Pierson et al., 2007). BHK21, K562, Vero, and
C6/36 Aedes albopictus cells were propagated as described (Pierson et al.,
2007). Mouse MAbs against WNV E (E16, E18, E24, and E34) and NS1
(17NS1) proteins have been described (Chung et al., 2006; Oliphant et al.,
2005). The 2H2 (anti-DENV prM) and 4G2 (anti-flavivirus E) MAbs also have
been described (Gentry et al., 1982).
Anti-Chikungunya E1 (CHIK-E3) and E2 (CHIK-E9 and CHIK-E11) MAbs
were generated in our laboratory and will be reported elsewhere (P. Pal,
J. Brien, and M.S.D., unpublished data). The biotinylated anti-mouse MBL-C
mAb and recombinant mouse MBL-C were purchased (R&D Systems), as
was the biotinylated anti-mouse C3 antibody (Cedarlane). DMJ and mannan
were obtained commercially (Calbiochem and Sigma, respectively).
Virus Stocks
The two-plasmid WNV NY99 infectious cDNA clone was used to create wild-
type and mutant D67NWNV. Single amino acid substitutions were introduced
by site-directed mutagenesis as described previously (Beasley et al., 2005).
WNV was passaged once in C6/36, BHK21, or Vero cells. BHK21 cells were
used to measure viral titers of infected cells by plaque assay (Diamond
et al., 2003). DENV type 1 (Western Pacific-74) and type 2 (16681) were prop-
agated in C6/36 or BHK21 cells. The CHIKV (strain 142, S. Higgs) and SINV
(strain 39HK, W. Klimstra) were propagated in C6/36 cells.
Serum Neutralization of Virus
For neutralization experiments, virions (103 PFU of WNV, 2.5 3 102 PFU of
DENV-2, 83 102 PFU of CHIKV, or 103 PFU of SINV) were incubatedwith naive
mouse serum (untreated or heat inactivated at 56C for 30 min) diluted in
gelatin veronal buffer with Mg2+ and Ca2+ (GVB2+) for 1 hr at 37C. Samples
were added to BHK21 cells and incubated for 1 hr at 37C. Cells were washed,
overlaid with 1% agarose in Minimal Essential Media (MEM) containing 4%
FBS, and cultured for 2 (CHIKV or SINV), 3 (WNV), or 5 (DENV) days at
37C. Plaques were counted following formaldehyde fixation and crystal violet
staining.
Infection of Dendritic Cells
Dendritic cells were generated from bone marrow of wild-type C57BL/6 mice
and cultured as described previously (Daffis et al., 2007). Cells were infected
with WNV at an moi of 0.1 for 1 hr at 37C. After culturing for 24 hr, superna-
tants containing infectious virus were analyzed by plaque assay.
Virolysis Assay
To test for serum-induced virolysis, 104 PFU of C6/36 cell-derived WNV
(diluted in GVB2+) was incubated with 10% (final concentration) heat inacti-
vated or untreated C57BL/6 wild-type serum, or serum from MBL-A/ 3
MBL-C/ mice. As a positive control, 0.1% NP-40 was added. Samples
were incubated for 1 hr at 37C, and 1 mg/ml RNase A was added. After anst & Microbe 8, 186–195, August 19, 2010 ª2010 Elsevier Inc. 193
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Proteinase K (EZBioResearch) for 20min at 37C. Viral RNAwas isolated using
the QiaAmp Viral RNA kit and measured by qRT-PCR (Samuel et al., 2006).
Virus Clearance Assays
For evaluation of clearance of WNV from the bloodstream, mice were inocu-
lated i.v. with 5 3 104 PFU of insect cell-derived wild-type or D67N mutant
in PBS. Blood samples were collected at 30 min and 3 hr after inoculation.
At 6 hr, micewere euthanized and bloodwas harvested. For DENV-1 clearance
experiments, mice were inoculated i.v. with 106 PFU of DENV-1, and blood
samples were collected at 10 min, 30 min, and 3 hr after inoculation. Blood
was clotted on ice for 30–60 min and centrifuged for 5 min at 10,0003 g, after
which serum was harvested and frozen at80C. Viral RNA was isolated from
20 ml serum of each sample using the QiaAmp Viral RNA kit. Viral RNA was
measured by qRT-PCR using WNV-specific primers and probe (Samuel
et al., 2006) or DENV group-specific primers and a DENV-1-probe (Callahan
et al., 2001).
Western Blots
For analysis of E protein migration patterns of wild-type WNV and glycosyla-
tion variants, virus was diluted in nonreducing SDS sample loading buffer,
incubated at 95C for 5 min, and electrophoresed on 10% Bis-Tris gels.
Protein was transferred onto PVDF membranes and blocked overnight
in 5% nonfat milk powder in PBS supplemented with 0.05% Tween 20.
Membranes were incubated with the WNV E protein reactive mAb E18
(1 mg/ml) for 1 hr at RT, washed, and incubated with HRP-conjugated goat
anti-mouse IgG antibody (Thermo Scientific) for 1 hr at RT. Membranes were
developed using ECL reagent (Amersham).
For evaluation of Endo H and PNGase F sensitivity of E protein N-linked
glycans, virus was digested with PNGase F (100 U) or Endo H (1000 U) accord-
ing to the manufacturer’s instruction (New England Biolabs) and then pro-
cessed by western blotting. For detection of CHIKV E proteins, the mouse
anti-E2 mAb CHIK-E11 (at 1 mg/ml) and anti-E1 mAb CHIK-E3 (1:15 diluted
hybridoma supernatant) were used.
MBL Binding and C3 Deposition Experiments and Virus Attachment
and Fusion Assays
MBL and C3 binding to WNV or CHIKV were evaluated using a virus capture
ELISAwith mAb-coatedmicrotiter plates as described (Vogt et al., 2009). Virus
attachment and fusion assays were based on published protocols (Nybakken
et al., 2005; Thompson et al., 2009). Detailed descriptions of these assays are
provided in the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures, Supplemental Experimental
Procedures, and Supplemental References and can be found with this article
online at doi:10.1016/j.chom.2010.07.007.
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